Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Red candles
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(42)
•••
Comment by Rawrasauruson Aug 18, 2021 8:44pm
131 Views
Post# 33728244

RE:RE:RE:Red candles

RE:RE:RE:Red candles

Yeah, the penny flippers trade this alot so it's defnitely scalpable if that's your vibe. My point was just that massive swings tend to go off of binary news events that are a bit harder to predict.

Unfortunately, we're in limbo for the next few weeks to a month unless some news kicks down the pike earlier that confirms one side or the other. The stock is massively shorted atm with almost half the float being sold short. It could definitely continue going down, but news confirming validity or sampling error would also turn this into a massive short squeeze. You kinda just have to place your bet regarding how you think the science will shake out or scalp in and out for smaller gains with the intention of getting back in once news has been released. That is much easier if you are on the CDN side instead of the USD side though since USD has next to no liquidity.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities